Southwestern
Click Here to Subscribe!

E-Health Services

Daily Health News

  Latest News
  FDA Approvals
  FYI

Health Information

Newsletter Topics

Allergy
Anxiety
Arthritis
Blood Pressure
Breast Cancer
Cancer
Depression
Diabetes
Exercise / Fitness
Female Urological Disorders
Gastrointestinal Health
Healthy Diet
Heart Disease
Men's Health
Neurology
Orthopedics
Pain Management
Parenting
Pediatrics
Pregnancy
Senior Caregiving
Sleep Disorders
Sports Medicine
Stroke
Weight Management
Women's Health
Women's Heart Health
Username: Password: Forgot password?
Remember me next time.
 FDA Approvals
Return to
Daily Health Main Page.

  1st Drug for Tardive Dyskinesia Approved
 
  Condition characterized by involuntary movement of the jaw, lips and tongue

 

WEDNESDAY, April 12, 2017 (HealthDay News) -- Ingrezza (valbenazine), the first drug to treat adults with the neurological disorder tardive dyskinesia, has been approved by the U.S. Food and Drug Administration.

The disorder is characterized by repetitive involuntary movements, usually of the jaw, lips and tongue. Affected people may stick out the tongue, smack the lips, involuntarily move the arms and legs, and have trouble breathing, the FDA said in a news release.

The disorder may be a side effect of older antipsychotic medications to treat conditions such as schizophrenia, depression or bipolar disorder. It's not known why some users of these medications develop tardive dyskinesia, while others don't, the agency said.

"Tardive dyskinesia can be disabling and can further stigmatize patients with mental illness," said Dr. Mitchell Mathis, director of the FDA's Division of Psychiatry Products. "Approving the first drug for the treatment of tardive dyskinesia is an important advance for patients suffering with this condition."

Ingrezza's effectiveness was established in a clinical study of 224 people that compared the drug to a placebo. Potential side effects included sleepiness and abnormal heartbeat. Anyone taking Ingrezza should not drive or use heavy machinery until the effects of the drug on the person are known, the FDA warned.

Approval of Ingrezza was given to Neurocrine Biosciences, based in San Diego.

More information

To learn more, visit the FDA.

  Print
 
 More  FDA Approvals
 
   •  FDA Approves Hep C Drugs for Kids 12 and Older
  Previously allowed only for adults
 
   •  FDA Approves 1st Direct-to-Consumer Genetic Risk Tests
  They screen for gene variants linked to 10 diseases and conditions
 
   •  Ocrevus Approved to Treat Severe Form of Multiple Sclerosis
  First drug sanctioned in U.S. for primary progressive MS
 
   •  Dupixent Approved to Treat Eczema
  When topical medication doesn't work
 
Health Content Provided By:
The health content is provided for informational and educational purposes. It is intended for the general population and may not reflect specific conditions or risk of an individual or segment of the population. Therefore, it is not intended to be a substitute for professional medical advice, consultation, treatment or diagnosis. Always seek the advice of your physician or other qualified health provider with questions. Never disregard professional medical advice or delay in seeking it because of information obtained through these services.
E-Home | E-Health Services | Sample News | Subscribe | Feedback | Contact Us | Privacy Policy | Terms & Conditions
 
© 2012 SOUTHWESTERN MEDICAL CENTER · 5602 SW LEE BLVD · LAWTON, OKLAHOMA 73505 · 580-531-4700 · SITEMAP · PRIVACY POLICY · TERMS & CONDITIONS
 
ABOUT US SERVICES & TECHNOLOGY FOR PATIENTS & GUESTS FOR PHYSICIANS FOR EMPLOYEES COMMUNITY CAREERS